Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 17;10(2):72.
doi: 10.3390/metabo10020072.

Metabolomics in Psychiatric Disorders: What We Learn from Animal Models

Elke Humer  1 , Thomas Probst  1 , Christoph Pieh  1
Affiliations
Review

Metabolomics in Psychiatric Disorders: What We Learn from Animal Models

Elke Humer et al. Metabolites. .

Abstract

Biomarkers are a recent research target within biological factors of psychiatric disorders. There is growing evidence for deriving biomarkers within psychiatric disorders in serum or urine samples in humans, however, few studies have investigated this differentiation in brain or cerebral fluid samples in psychiatric disorders. As brain samples from humans are only available at autopsy, animal models are commonly applied to determine the pathogenesis of psychiatric diseases and to test treatment strategies. The aim of this review is to summarize studies on biomarkers in animal models for psychiatric disorders. For depression, anxiety and addiction disorders studies, biomarkers in animal brains are available. Furthermore, several studies have investigated psychiatric medication, e.g., antipsychotics, antidepressants, or mood stabilizers, in animals. The most notable changes in biomarkers in depressed animal models were related to the glutamate-γ-aminobutyric acid-glutamine-cycle. In anxiety models, alterations in amino acid and energy metabolism (i.e., mitochondrial regulation) were observed. Addicted animals showed several biomarkers according to the induced drugs. In summary, animal models provide some direct insights into the cellular metabolites that are produced during psychiatric processes. In addition, the influence on biomarkers due to short- or long-term medication is a noticeable finding. Further studies should combine representative animal models and human studies on cerebral fluid to improve insight into mental disorders and advance the development of novel treatment strategies.

Keywords: animal models; biomarkers; metabolomics; psychiatric disorders.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Wang W., Guo H., Zhang S.-X., Li J., Cheng K., Bai S.-J., Yang D.-Y., Wang H.-Y., Liang Z.-H., Liao L., et al. Targeted Metabolomic Pathway Analysis and Validation Revealed Glutamatergic Disorder in the Prefrontal Cortex among the Chronic Social Defeat Stress Mice Model of Depression. J. Proteome Res. 2016;15:3784–3792. doi: 10.1021/acs.jproteome.6b00577. - DOI - PubMed
    1. Sethi S., Brietzke E. Omics-Based Biomarkers: Application of Metabolomics in Neuropsychiatric Disorders. Int. J. Neruopsychopharmacol. 2016;19 doi: 10.1093/ijnp/pyv096. - DOI - PMC - PubMed
    1. Guest P.C., Guest F.L., Martins-de Souza D. Making Sense of Blood-Based Proteomics and Metabolomics in Psychiatric Research. Int. J. Neruopsychopharmacol. 2016;19 doi: 10.1093/ijnp/pyv138. - DOI - PMC - PubMed
    1. Cuthbert B.N., Insel T.R. Toward the future of psychiatric diagnosis: The seven pillars of RDoC. BMC Med. 2013;11:126. doi: 10.1186/1741-7015-11-126. - DOI - PMC - PubMed
    1. Biomarkers Definitions Working Group. Atkinson A.J., Jr., Colburn W.A., DeGruttola V.G., DeMets D.L., Downing G.J., Spilker B.A. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001;69:89–95. doi: 10.1067/mcp.2001.113989. - DOI - PubMed